Teladoc is the nation’s first telehealth provider and the industry’s “giant” in the 24/7 virtual visits and ...read more
23andMe is a consumer genetics company with a mission to become the Google of personalized healthcare. Halted in 2013 by the FDA because of regulatory concerns, the company has endured twists and turns and was approved to re-launch a scaled- back version of its services in October 2015. Today the company has more than 1.2 million customers worldwide, has now received FDA clearance to inform consumers of their risks for 10 different genetic conditions, has partnerships with Pfizer, Genentech, and others, launched a new therapeutics division, and is valued at more than $1 billion.
This content is restricted to site members. If you are an existing user, please log in. New users may register below.